Observational Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Aug 15, 2023; 14(8): 1280-1288
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1280
Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients
Xiao-Min Huang, Xing Zhong, Yi-Jun Du, Yan-Yun Guo, Tian-Rong Pan
Xiao-Min Huang, Xing Zhong, Yi-Jun Du, Yan-Yun Guo, Tian-Rong Pan, Department of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China
Author contributions: Pan TR took part in the study coordination; Huang XM took part in the study execution, data collection, and discussions; Zhong X, Du YJ, Guo YY, and Pan TR took part in the study design, supervision, and drafting of the manuscript; Zhong X, Du YJ, and Guo YY contributed to the data analyses.
Supported by the Clinical Research and Cultivation Plan Project of the Second Affiliated Hospital of Anhui Medical University, No. 2021LCYB17.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (Approval No. YX2019-055).
Informed consent statement: All study participants provided informed written consent prior to study enrolment.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tian-Rong Pan, MD, Chief Physician, Department of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Economic and Technological Development Zone, Hefei 230601, Anhui Province, China. ptr1968@163.com
Received: April 19, 2023
Peer-review started: April 19, 2023
First decision: April 28, 2023
Revised: May 16, 2023
Accepted: June 21, 2023
Article in press: June 21, 2023
Published online: August 15, 2023
Processing time: 114 Days and 2.6 Hours
ARTICLE HIGHLIGHTS
Research background

The background of the research is the increasing prevalence and challenges associated with type 2 diabetes mellitus (T2DM). The study explores the causes of T2DM and the limitations of current treatment options.

Research motivation

The motivation behind the research is to address the limitations of existing drugs for T2DM treatment and explore the potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a more effective therapeutic option.

Research objectives

The objectives of the research are to compare the blood glucose control effects of weekly and daily formulations of GLP-1RAs, analyze glucose excursion and inflammation in overweight or obese patients with T2DM, and evaluate the safety and clinical application prospects of the weekly formulation.

Research methods

The study involved administering weekly and daily formulations of GLP-1RA to the participants and measuring various parameters such as fasting blood glucose, mean blood glucose, glucose excursion, lipid levels, and inflammation markers. Glucose dynamic tests were conducted to assess blood glucose fluctuations.

Research results

The results indicated that the weekly formulation of GLP-1RA had superior blood glucose control effects compared to the daily formulation. It resulted in lower mean blood glucose levels, reduced glucose excursion, and improved lipid profiles. Additionally, the weekly formulation showed a greater decrease in inflammation markers.

Research conclusions

Based on the findings, the research concludes that the weekly formulation of GLP-1RA is more effective in controlling blood glucose levels, inhibiting inflammation, and reducing adverse reactions in obese patients with T2DM. It suggests that the weekly formulation has promising clinical applications and should be considered for wider implementation.

Research perspectives

To investigate the effects of weekly and daily formulations of GLP-1RA on glucose excursion and inflammation in overweight and obese patients with type 2 diabetes.